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Running head: Simplicity and Practicality Matter 
 
 
 
Atrial fibrillation in an elderly patient requires oral anticoagulant (OAC) treatment, and contemporary 
international guidelines recommend treatment for atrial fibrillation patients at 75 years or older 
1,2
. 
Substantial evidence (mostly in favour) of non-vitamin K antagonist oral anticoagulants (NOACs), in 
comparison with warfarin, has emerged over the past decade. In particular, the benefits from a lower 
risk of intracranial bleeding and the non-requirement for monitoring of anticoagulant effects have 
driven the uptake of NOACs as the preferred choice for stroke prevention in atrial fibrillation, although 
some regional differences are evident
3
.  
A heap of observational studies comparing NOACs with warfarin have been published: some focus on 
particular outcomes or specific drugs 
4–6
, some maintain focus on particular subgroups within the broad 
atrial fibrillation population 
7,8
. However, these publications shared a common quest to understand the 
association between drug exposure and the outcome – in other words, the etiological course or the 
causal link between being exposed and the outcome. This is not trivial to establish using observational 
data, and results can only be interpreted as being causal treatment effects under very strong 
assumptions 
9
. Nevertheless, causation should be what we seek, and thought leaders argue that 
researchers need more clearly to articulate the causal inference path when stating the research question 
10,11
.  
In this issue of the journal, Patti et al. sought to compare exposure to NOACs vs warfarin on a net 
composite endpoint consisting of major bleeding, stroke, transient ischemic attack, systemic embolism, 
acute coronary syndrome, and coronary revascularization
12
. A weight was applied to each individual 
outcome to accommodate for the difference in severity of the studied outcomes.  
The principles of applying weights to incidence rates are well-known, and may provide useful clinical 
information in terms of net clinical benefit 
13
. However, a more specific approach has also been 
suggested, where clinicians rebalance weights applied to expected outcomes such as major bleeding 
and ischemic stroke, reflecting safety and efficacy in well-reasoned net clinical benefit 
14
. 
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Conducting a causal, observational drug-outcome study is challenging and treatment effect estimates 
will be biased due to confounding, selection biases and other systematic errors. Incomplete observation 
or adjustment for confounding factors inevitably leaves residual confounding and leads to bias in the 
treatment effect estimate. A clear distinction needs to be made between “confounders” and 
“confounding” 
15
. Selection of covariates in an adjustment model must be based on subject matter 
knowledge – not on data availability or model selection based purely on statistical structure in the data. 
Patti et al. applied a stepwise approach of covariate inclusion into a logistic regression model to obtain 
associated odds ratio for the outcome under the two treatment exposures. While chance cannot be ruled 
out in favour of this approach, there is a risk of ruling out confounding factors that are very well 
established in prior research, and often common clinical knowledge.  
In the current study, exclusion of sex as a potential confounding factor is an omission of this kind. It is 
highly likely this biased the results. Consideration of confounding factors can be helped by mapping 
out, with a graphical model notation, known causal pathways and the segways of confounded 
association that may bias the treatment-outcome inference 
16
. 
While research into net clinical benefit is of some value to guide clinical practice, the results from the 
study by Patti et al. require confirmation in other registries where state-of-the-art epidemiological 
approaches have been applied. Conducting robust research with treatment exposure and associated 
outcome from observational requires a rigid and perceptive approach, which is clear and practical to 
apply. 
Net clinical benefit analyses are also bedevilled by assumptions that all components of the net clinical 
benefit outcome carry equal weight, but they do not. Different approaches to defining net clinical 
benefit have been proposed, ranging from the simple balancing of ischaemic stroke reduction against a 
weighted increase in serious bleeding, to more complex formulae derived from regression models. 
Which approach is right? Clinical risk assessment in patients with atrial fibrillation has to balance 
(often marginal) improvements in prediction against the need for clarity and practicality
17,18
. Indeed, 
many risk scores have been proposed and validated in diverse atrial fibrillation cohorts, which can 
inform net clinical benefit calculation assumptions. Ultimately, the default for the management of atrial 
fibrillation patients should be to offer stroke prevention, unless the patients can be defined as ‘low 
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risk’
1,2
. Thus, guidelines have moved towards offering simple and pragmatic approaches to decision 
making in the AF patient management pathway, which can be distilled down to the simple ABC 
pathway (‘A’ Avoid stroke with Anticoagulation’; Better symptom management, with patient-centred, 
symptom directed use of rate or rhythm control; and ‘C’ Cardiovascular risk and comorbidity 
management, including lifestyle and patient values and preferences)
19
. Importantly, compliance with 
the ABC pathway has been shown to be associated with improved clinical outcomes and reduced 
healthcare costs
20–22
. 
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